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1. Introduction
  Melioidosis, a disease of public health importance in 
Southeast Asia and Northern Australia, of late has shown 
an increasing trend in India, particularly Southern India. 
The causative microorganism, Burkholderia pseudomallei 
(B. pseudomallei), infects individuals with predisposing 
factors like diabetes mellitus and alcoholism. Therapeutic 
approaches consist of the clinical resolution of acute 
infection (acute phase) followed by the eradication 
of residual intracellular infection to prevent relapse 
(maintenance phase). In India, the first-line regimen in the 
acute phase is intravenous ceftazidime. We report a case of 
ceftazidime resistant B. pseudomallei, successfully treated 
by imipenem. This case of disseminated melioidosis re-
emphasizes the need to monitor the trend of B. pseudomallei 
in India, particularly the development of ceftazidime 
resistance as well as a possible role of carbapenem in 
treating melioidosis in developing countries.
2. Case report
  A 39 year old male from Rajamundry, a coastal village of 
Andhra Pradesh, India was referred to our hospital with a 
history of jaundice of 2 days, abdominal pain and vomiting 
for 10 days. He had history of recurrent, remittent type 
of fever, loss of appetite and weight loss in last 8 months 
which was treated outside with antimalarials and multiple 
oral antibiotics whose precise dosage and duration could 
not be known. He also had pain and swelling of the left 
elbow joint for last 1 month. His prior history included a 
recently diagnosed (4 months back) non-insulin dependent 
diabetes mellitus with irregular treatment. On admission, 
physical examination revealed a temperature of 39 ℃, 
a blood pressure of 100/70 mmHg, respiratory rate of
24/min. He was icteric and dehydrated. His vitals 
were stable. General examination revealed extensive 
oropahryngeal thrush and swelling and tenderness over the 
medical epicondyle of the left elbow joint. Examination 
of the abdomen revealed hepatosplenomegaly. Initial 
laboratory investigations revealed elevated TLC (28 900/mm3 
with 90% polymorphs, elevated C reactive protein (315 mg/
L) and elevated transaminases: aspartate aminotransferase 
144 IU/L and alanine aminotransferase 68 IU/L. Despite 
the absence of respiratory symptoms and a normal initial 
chest X-ray on the day of admission, the patient developed 
respiratory distress requiring O2 support, the following day, 
due to severe bilateral abscess-forming pneumonia and 
was started on IV imipenem-cilastin (500 mg /6 hours). An 
X-ray and a computed tomography of chest at 36 hours 
after admission showed bilateral infiltrates with nodular 
lesions probably corresponding to micro-abscesses, along 
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with moderate pleural effusion. Ultrasound scans of the 
abdomen and pelvis revealed hepatosplenomegaly with 
multiple hepatic and splenic abscesses. Ultrasound scan of 
the left elbow joint revealed well-defined thick, collection 
measuring about 3.9 cm 伊 2.6 cm. US guided aspirate was 
sent for culture. Gram negative rods were isolated from 
blood culture as well as joint aspirate after 24 hours of 
incubation. On sheep blood agar, small, smooth, circular, 
non-haemolytic colonies were obtained after 24 hours of 
incubation, which subsequently changed over to large, flat, 
dry, and wrinkled with central umbonation after 96 hours of 
incubation. MacConkey agar showed non-lactose fermenting 
colonies. Microscopy from culture revealed Gram negative, 
medium sized, straight and motile bacilli. The isolate was 
subsequently identified as B. pseudomallei (MicroScan 
Walkaway 40) and was resistant to ceftazidime (MIC>16 毺
g/mL) and sensitive to imipenem (MIC<4 毺g/mL) and co-
trimoxazole (MIC<2/38 毺g/mL). Over the next week, the 
patient steadily improved clinically on imipenem and was 
discharged on TMP-SMX to complete the 24-week course. 
1 double strength tablet every 12 h was given for 6 months. 
At this time, he continues to be asymptomatic and his chest 
radiography and ultra sonography abdomen and pelvis are 
normal. 
3. Discussion
  Melioidosis has shown an increasing trend in Southern 
India in recent years[1]. Saravu et al analyzed the 
epidemiological and clinical profile of melioidosis in 
southern India over a period of six years, which documented 
a 6-fold increase in the number of cases in 2006 and 2007 
as compared to 2001[1]. Diabetes mellitus was the major 
predisposing factor in 68% of cases[1]. Disseminated 
melioidosis was the most common (68%) presentation, 
followed by the septicaemic (28%) and localized cutaneous 
abscesses (16%)[1]. In our report, uncontrolled diabetes 
mellitus was the only predisposing factor. The patient was 
a government service person by occupation and had no 
relevant history of occupational/recreational exposure. 
  Several previous randomized, controlled trials have 
examined intensive phase interventions in severe 
melioidosis and were the basis of ceftazidime-based 
regimens[2,3]. Ceftazidime has benefit in the treatment of 
this disease in a sequential open-label randomized trial 
of ceftazidime against chloramphenicol-doxycycline-
trimethoprim-sulfamethoxazole (known as conventional 
therapy) in severe disease[2].
  Resistance to ceftazidime in the present isolate is 
noteworthy as till date all the B. pseudomallei isolates 
reported from India retained sensitivity to third generation 
cephalosporins, particularly ceftazidime[1]. The development 
of resistance to ceftazidime, the drug of choice for 
melioidosis, in a B. pseudomallei isolate during therapy 
with this antibiotic was recently reported by Chia Te Kung 
et al in a case of mediastinitis[4]. The authors speculated 
the subsequent emergence of ceftazidime resistance (MIC, 
48 毺g/mL) in the B. pseudomallei isolate [the original 
isolate recovered from blood culture was susceptible to 
ceftazidime (MIC, <8 毺g/mL)] from the mediastinal necrotic 
lymphatic tissue might have resulted from the microbe's 
prior prolonged exposure to the suboptimal concentrations 
of ceftazidime in the lymphatic niche[4]. A single clonal 
population of the culprit B. pseudomallei evolving into 
subpopulations with differing ceftazidime susceptibilities 
(i.e. coexistence of ceftazidime-susceptible, ceftazidime-
intermediate and ceftazidime-resistant subpopulations) as a 
result antibiotic selective pressure was also reported recently 
in a diabetic patient with pulmonary melioidosis under 
ceftazidime treatment[5]. This together with the report of 
high mortality rate (35%) of patients with melioidosis treated 
with ceftazidime, to which the B. pseudomallei isolates 
were susceptible, highlights a possible role of carbapenem 
in the treatment of melioidosis in developing countries[6,7]. 
Carbapenems have some benefits over ceftazidime for the 
treatment of melioidosis given that they are more active in 
vitro, display a post-antibiotic effect and have association 
with decreased endotoxin release[8,9].
  The diagnosis of melioidosis requires clinical vigilance 
and an intensive microbiological workup. To our knowledge, 
this is perhaps the first report of ceftazidime resistant
B. pseudomallei from the Indian sub-continent. This 
together with the increasing incidence of melioidosis 
in Southern India raises the alarm for a suspicion of 
melioidosis in the differential diagnosis of sepsis in diabetic 
patients in this area. In conclusion, we suggest that all B. 
pseudomallei isolates should carefully be evaluated for their 
sensitivity to ceftazidime, as traditionally it has been the 
treatment of choice in the acute/intensive phase. 
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